S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000967968.05170.e0 |
| _version_ | 1827332474905034752 |
|---|---|
| author | Rabi Hanna Haydar Frangoul Christopher Mckinney Luis Pineiro Markus Mapara Kai-Hsin Chang Michael Jaskolka Keunpyo Kim Maha Rizk Olubunmi Afonja Adebayo Lawal Mark Walters |
| author_facet | Rabi Hanna Haydar Frangoul Christopher Mckinney Luis Pineiro Markus Mapara Kai-Hsin Chang Michael Jaskolka Keunpyo Kim Maha Rizk Olubunmi Afonja Adebayo Lawal Mark Walters |
| author_sort | Rabi Hanna |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:01:26Z |
| format | Article |
| id | doaj.art-eb39d9d9fabf4d00bd0d947210306f26 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:01:26Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-eb39d9d9fabf4d00bd0d947210306f262024-03-03T03:24:50ZengWileyHemaSphere2572-92412023-08-017e05170e010.1097/01.HS9.0000967968.05170.e0202308003-00166S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYMERabi Hanna0Haydar Frangoul1Christopher Mckinney2Luis Pineiro3Markus Mapara4Kai-Hsin Chang5Michael Jaskolka6Keunpyo Kim7Maha Rizk8Olubunmi Afonja9Adebayo Lawal10Mark Walters111 Cleveland Clinic, Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland, United States2 Children’s Hospital at TriStar Centennial, Sarah Cannon Center for Blood Cancer, Nashville, United States3 Anschutz Medical Campus, Children’s Hospital of Colorado, Aurora, CO, United States4 Baylor University Medical Center, Blood and Marrow Transplant Program and Marrow Processing Laboratory,, Dallas, TX, United States5 Columbia University Irving Medical Center, Bone Marrow Transplantation and Cell Therapy Program, New York City, NY, United States6 Editas Medicine, Inc., Cambridge, MA, United States6 Editas Medicine, Inc., Cambridge, MA, United States6 Editas Medicine, Inc., Cambridge, MA, United States6 Editas Medicine, Inc., Cambridge, MA, United States6 Editas Medicine, Inc., Cambridge, MA, United States6 Editas Medicine, Inc., Cambridge, MA, United States7 University of California, San Francisco and Benioff Children’s Hospital, School of Medicine, Oakland, CA, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000967968.05170.e0 |
| spellingShingle | Rabi Hanna Haydar Frangoul Christopher Mckinney Luis Pineiro Markus Mapara Kai-Hsin Chang Michael Jaskolka Keunpyo Kim Maha Rizk Olubunmi Afonja Adebayo Lawal Mark Walters S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME HemaSphere |
| title | S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title_full | S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title_fullStr | S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title_full_unstemmed | S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title_short | S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME |
| title_sort | s264 edit 301 shows promising preliminary safety and efficacy results in the phase i ii clinical trial ruby of patients with severe sickle cell disease using highly specific and efficient ascas12a enzyme |
| url | http://journals.lww.com/10.1097/01.HS9.0000967968.05170.e0 |
| work_keys_str_mv | AT rabihanna s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT haydarfrangoul s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT christophermckinney s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT luispineiro s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT markusmapara s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT kaihsinchang s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT michaeljaskolka s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT keunpyokim s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT maharizk s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT olubunmiafonja s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT adebayolawal s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme AT markwalters s264edit301showspromisingpreliminarysafetyandefficacyresultsinthephaseiiiclinicaltrialrubyofpatientswithseveresicklecelldiseaseusinghighlyspecificandefficientascas12aenzyme |